The novel molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl) -phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells

FEBS Journal

Volumn 276, Issue 15, 2009, Pages 4037-4050

  Ho, Ka Kei ^a   Rosivatz, Evelyn ^b   Gunn, Richard M ^b,c   Smith, Mark E B ^c   Stavropoulou, Alexandra V ^a   Rosivatz, Erika ^b   Numbere, MacBa G ^c   Wong, John B ^c   Lafitte, Valerie G H ^c   Behrendt, Jonathan M ^c   Myatt, Stephen S ^a   Hailes, Helen C ^b   Woscholski, Rüdiger ^b   Lam, Eric W F ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Akt; Cancer cells; JNK; PI3K; Small molecules

Indexed keywords

2 [5 (2 CHLOROETHYL) 2 ACETOXY BENZYL] 4 (2 CHLOROETHYL) PHENYL ACETATE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GLYCOPROTEIN E1; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME REPRESSION; FIBROBLAST; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; FIBROBLASTS; HUMANS; MAP KINASE KINASE 4; MICE; PACLITAXEL; PHENYLACETATES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; VINYL CHLORIDE;

EID: 68249103085     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07112.x     Document Type: Article

References (38)

1. Leevers SJ, Vanhaesebroeck B Waterfield MD (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 11, 219 225.
2. Wymann MP Marone R (2005) Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17, 141 149.
3. Shaw RJ Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424 430.
4. Gunn RM Hailes HC (2008) Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. J Chem Biol 1, 49 62.
5. Vivanco I Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489 501.
6. Hanahan D Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57 70.
7. Engelman JA, Luo J Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7, 606 619.
8. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554. (Pubitemid 38541907)
9. Dillon RL, White DE Muller WJ (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26, 1338 1345.
10. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64, 280 285.
11. Sansal I Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22, 2954 2963.
12. Dancey JE (2006) Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5, 1065 1073.
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356, 2271 2281. (Pubitemid 46849157)
14. Huang WC (2008) Is advanced renal cell carcinoma best treated with temsirolimus, interferon alpha, or both? Nat Clin Pract Oncol 5, 16 17.
15. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66, 1500 1508.
16. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM Fruman DA (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL leukemia cells. J Clin Invest 118, 3038 3050.
17. Byrne RD, Rosivatz E, Parsons M, Larijani B, Parker PJ, Ng T Woscholski R (2007) Differential activation of the PI 3-kinase effectors AKT/PKB and p70 S6 kinase by compound 48/80 is mediated by PKCalpha. Cell Signal 19, 321 329.
18. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, Burgering BM, Coombes RC Lam EW (2006) Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 66, 212 220.
19. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC Lam EW (2003) FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278, 49795 49805.
20. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH et al. (2001) BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20, 6123 6131.
21. Luo Y, Rockow-Magnone SK, Joseph MK, Bradner J, Butler CC, Tahir SK, Han EK, Ng SC, Severin JM, Gubbins EJ et al. (2001) Abrogation of G2 checkpoint specifically sensitizes p53 defective cells to cancer chemotherapeutic agents. Anticancer Res 21, 23 28.
22. Schmidt M Bastians H (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 10, 162 181.
23. Connell-Crowley L, Harper JW Goodrich DW (1997) Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8, 287 301.
24. Zarkowska T, U S, Harlow E Mittnacht S (1997) Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs. Oncogene 14, 249 254.
25. Driscoll B, T'Ang A, Hu YH, Yan CL, Fu Y, Luo Y, Wu KJ, Wen S, Shi XH, Barsky L et al. (1999) Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb. J Biol Chem 274, 9463 9471.
26. Eguchi T, Takaki T, Itadani H Kotani H (2007) RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene 26, 509 520.
27. Alessi DR Cohen P (1998) Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8, 55 62.
28. Hresko RC Mueckler M (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280, 40406 40416.
29. Sarbassov DD, Guertin DA, Ali SM Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098 1101.
30. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J Su B (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125 137.
31. Volarevic S, Stewart MJ, Ledermann B, Zilberman F, Terracciano L, Montini E, Grompe M, Kozma SC Thomas G (2000) Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science 288, 2045 2047.
32. McMahon LP, Choi KM, Lin TA, Abraham RT Lawrence JC Jr. (2002) The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 22, 7428 7438.
33. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177 189.
34. Selimovic D, Hassan M, Haikel Y Hengge UR (2008) Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell Signal 20, 311 322.
35. Alexandre J, Hu Y, Lu W, Pelicano H Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67, 3512 3517.
36. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, Panelli S, Valladares A, Perez L, Klein R Nebreda AR (2000) Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6, 109 116.
37. Madureira PA, Varshochi R, Constantinidou D, Francis RE, Coombes RC, Yao KM Lam EW (2006) The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem 281, 25167 25176.
38. Lam EW, Choi MS, van der Sman J, Burbidge SA Klaus GG (1998) Modulation of E2F activity via signaling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells. J Biol Chem 273, 10051 10057.